ICH M9 - reverse engineering? [Regulatives / Guidelines]

posted by MSimoes – Portugal, 2020-09-16 16:01 (73 d 13:48 ago) – Posting: # 21922
Views: 466

Dear BEBAC team,

Do you have experience with biowaivers and ICH M9 guideline?
When the M9 guidance mentions that we should have a formulation "qualitatively the same and quantitatively similar", especially for BCS class III drugs, how should be the quantitative formulation of the RLD justified? Is literature data enough, or do we need reverse engineering - and in this case, what is the level required (Q2 or Q3)? Only one method for each attribute or orthogonal analysis required?

This is not easy for some specific formulations, and the M9 is not clear in these requirements.

Thanks in advance for sharing your experience!

Kind regards,
Marta

Regards,
MSimoes

Complete thread:

Activity
 Admin contact
21,216 posts in 4,427 threads, 1,481 registered users;
online 15 (0 registered, 15 guests [including 8 identified bots]).
Forum time: Sunday 04:50 CET (Europe/Vienna)

Half the harm that is done in this world
Is due to people who want to feel important.    T. S. Eliot

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5